Sarepta Therapeutics.
biopharmaceutical company
- Reports this week
- 1
- Active events
- 1
- Connections
- 74
What's happening
Active this week
One to three months ago
Gone quiet
No new reports in 90+ days-
Sarepta Therapeutics, which develops precision genetic medicines for DMD, trades on the Nasdaq and is headquartered in Cambridge.Well supported4 reports
-
Both Sarepta Therapeutics and Citigroup provided market analysis on Sarepta's stock on July 9, 2026.Some support1 report
-
Royal Bank of Canada raised its price objective on Sarepta Therapeutics, which is listed on Nasdaq, with MarketBeat providing average ratings.Some support2 reports
-
Jim Cramer discussed Sarepta Therapeutics' investment potential, noting AI stocks benefit from Trump-era tariffs.Some support12 reports5 developments inside
-
FDA rejected a request to halt drug distribution, while the Trump administration provided tax benefits and natural gas prices tumbled.Some support1 report
-
The FDA is under scrutiny regarding safety concerns related to the drug ELEVIDYS, which involves Sarepta Therapeutics.Well supported14 reports
-
TD Cowen downgraded Sarepta Therapeutics stock due to increased probability of drug withdrawal pending FDA approval.Speculative1 report
-
The FDA advisory committee voted against a specific dosage for a GSK drug, leading to negative market sentiment affecting companies including Humana and Sarepta Therapeutics.Well supported21 reports
-
General negative market sentiment weighed on the biotech and pharmaceutical sectors in late July 2025.Some support9 reports2 developments inside
-
Sarepta Therapeutics is developing gene therapies for DMD. The FDA has mandated a black box warning for ALF due to patient deaths linked to the compound in trials.Some support1 report
-
Negative developments emerged on July 22, 2025, concerning the sector, including weakness in managed care providers, impacting companies like Humana and Sarepta Therapeutics.Some support3 reports
-
Arrowhead and Sarepta reached clinical and licensing milestones in their collaboration regarding siRNA programs.Some support1 report
-
Sarepta Therapeutics uses LinkedIn for investor communication and is based in Cambridge, Massachusetts.Some support1 report
-
Sarepta Therapeutics reported layoffs affecting workers at its Bedford campus.Some support1 report
-
Arrowhead received a milestone payment from Sarepta regarding their collaboration. Separately, Sanofi signed an asset purchase agreement with an Arrowhead subsidiary.Some support2 reports
-
Elanco is joining the S&P MidCap 400 index, Boehringer Ingelheim launched a new swine vaccine, and Sarepta Therapeutics is being replaced in the index.Some support2 reports
No events began in the chosen period. Widen it, or reset.
What's reaching Sarepta Therapeutics
Events traced to Sarepta Therapeutics, step by step, newest firstAround Sarepta Therapeutics this week
News at the entities that move Sarepta Therapeutics most-
FDA StructuralFDA issued a warning letter to NeoGen regarding a product quality defect on October 7, 2026.Moves Sarepta Therapeutics
-
Hoffmann-La Roche OperationalOmar Khwaja, a Fellow of the Royal College of Physicians, leads clinical research at Cancer Research UK.Moves Sarepta Therapeutics
-
Food and Drug Administration StructuralFDA ordered the recall of a batch of cow ghee from Patanjali Foods Limited in Madhya Pradesh.Moves Sarepta Therapeutics
-
Novartis OperationalBristol-Myers Squibb paused clinical trials following clinical setbacks reported by Novartis.Moves Sarepta Therapeutics
-
Royal Bank of Canada Mentioned togetherMorgan Stanley began coverage of Vylor with an 'overweight' rating, while Royal Bank of Canada authorized a $3.00 billion stock buyback plan.Moves Sarepta Therapeutics
-
MarketBeat Mentioned togetherMarketBeat used its stock screener tool to highlight Walmart.Moves Sarepta Therapeutics
Connections
The 16 strongest of 74, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
FDA Structural
The FDA formally regulates Sarepta Therapeutics, dictating product designation, safety warnings, and market distribution.
-
DMD Operational
Sarepta Therapeutics actively develops and focuses on treatments for Duchenne muscular dystrophy.
-
Arrowhead Pharmaceuticals Operational
The companies maintain a formal partnership for drug development, involving rights transfer, joint collaboration, and milestone payments.
-
Doug Ingram Operational
Ingram held a key role at Sarepta, influencing company guidance and operations before his retirement.
-
Severino Structural
Severino is projected to assume the role of CEO at Sarepta Therapeutics.
-
Hoffmann-La Roche Operational
Sarepta Therapeutics and Hoffmann-La Roche are actively collaborating on the development and contract manufacturing of the Elevidys gene therapy.
-
Novartis Operational
The companies are active competitors in the gene therapy space while also maintaining a formal collaboration agreement.
-
Food and Drug Administration Structural
The FDA formally regulates Sarepta Therapeutics through designations, investigations, and control over product shipments.
Show all 16 connections
-
MarketBeat Mentioned together
MarketBeat provides financial ratings and lists Sarepta Therapeutics within its stock screening and analysis tools.
-
Cambridge Shared context
Sarepta Therapeutics is headquartered in Cambridge, Massachusetts.
-
Citigroup Mentioned together
Both firms are mentioned as providers of market analysis regarding Sarepta Therapeutics stock.
-
Vinay Prasad Shared context
Vinay Prasad's regulatory actions and critiques influence the drug approval environment in which Sarepta operates.
-
Royal Bank of Canada Mentioned together
Royal Bank of Canada provided financial commentary by raising its price objective for Sarepta Therapeutics.
-
Benzinga Mentioned together
Benzinga, a financial news organization, reports on Sarepta Therapeutics' market developments, including price targets.
-
Nasdaq Shared context
Sarepta Therapeutics is a company listed and trades on the Nasdaq stock exchange.
-
AMD Mentioned together
The companies are co-mentioned in the context of general market trends and stock performance.
History
Events by the month they beganNovember 2026
1 eventJuly 2026
3 events- Sarepta Therapeutics, which develops precision genetic medicines for DMD, trades on the Nasdaq and is headquartered in Cambridge.
- Both Sarepta Therapeutics and Citigroup provided market analysis on Sarepta's stock on July 9, 2026.
- Royal Bank of Canada raised its price objective on Sarepta Therapeutics, which is listed on Nasdaq, with MarketBeat providing average ratings.
June 2026
14 events- BetterHelp competes for services previously driven by Teladoc, while both companies face market headwinds.
- Jim Cramer discussed Sarepta Therapeutics' investment potential, noting AI stocks benefit from Trump-era tariffs.
- FDA rejected a request to halt drug distribution, while the Trump administration provided tax benefits and natural gas prices tumbled.
- The FDA is under scrutiny regarding safety concerns related to the drug ELEVIDYS, which involves Sarepta Therapeutics.
- TD Cowen downgraded Sarepta Therapeutics stock due to increased probability of drug withdrawal pending FDA approval.
- The FDA advisory committee voted against a specific dosage for a GSK drug, leading to negative market sentiment affecting companies including Humana and Sarepta Therapeutics.
- General negative market sentiment weighed on the biotech and pharmaceutical sectors in late July 2025.
- Sarepta Therapeutics is developing gene therapies for DMD. The FDA has mandated a black box warning for ALF due to patient deaths linked to the compound in trials.
- Negative developments emerged on July 22, 2025, concerning the sector, including weakness in managed care providers, impacting companies like Humana and Sarepta Therapeutics.
- Arrowhead and Sarepta reached clinical and licensing milestones in their collaboration regarding siRNA programs.
- Sarepta Therapeutics uses LinkedIn for investor communication and is based in Cambridge, Massachusetts.
- Sarepta Therapeutics reported layoffs affecting workers at its Bedford campus.
- Arrowhead received a milestone payment from Sarepta regarding their collaboration. Separately, Sanofi signed an asset purchase agreement with an Arrowhead subsidiary.
- Elanco is joining the S&P MidCap 400 index, Boehringer Ingelheim launched a new swine vaccine, and Sarepta Therapeutics is being replaced in the index.